We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App





DiaSorin Showcases Latest Assays and Reagents for In-Vitro Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: LIAISON XS delivers a high technology solution for immunochemistry tests (Photo courtesy of DiaSorin)
Image: LIAISON XS delivers a high technology solution for immunochemistry tests (Photo courtesy of DiaSorin)

DiaSorin S.p.A. (‎Saluggia‎, Italy) is exhibiting its range of advanced diagnostic solutions at this year's WorldLab-EuroMedLab that are designed to help clinicians in the management of emergency patients.

At EuroMedLab Rome 2023, DiaSorin is presenting its industry-leading offering of fully-automated chemiluminescent immunoassay (CLIA) panels, designed specifically for diagnosing infectious diseases. The highlight of the event, however, is the LIAISON MeMed BV test - DiaSorin's groundbreaking solution for rapidly and accurately distinguishing between bacterial and viral infections. The LIAISON MeMed BV test is the first of its kind, a fully automated solution that uses data based on the host's response. This innovative test aids physicians in accurately distinguishing between bacterial and viral infections, thereby facilitating quicker, more informed decisions regarding treatment and patient management. Moreover, compared to conventional growth-based microbiology methods, this test enhances lab operational efficiency by saving time and reducing labor through its fully automated and high-throughput approach.

In addition, DiaSorin is highlighting the capabilities of its LIAISON XS analyzer - a high-tech solution for immunochemistry tests. The analyzer enables laboratories to boost both efficiency and clinical effectiveness for routine and specialty testing. Also on display at the event is the LIAISON XL, a fully automated chemiluminescence analyzer, designed to carry out complete sample processing (including sample pre-dilutions, sample and reagent dispensing, incubations, wash processes, etc.), measurement, and evaluation. The LIAISON XL, with its innovative features such as a fully automated solution, superior result quality, flexible configuration, and high efficiency, has the potential to significantly improve the productivity of immunoassay labs.

Related Links:
DiaSorin S.p.A.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.